Panel 1: Intellectual Property Rights and Biopharmaceutical Ecosystem Design

Katherine Rockett (Univ. of Essex), Pierre Regibeau (former Chief Competition Economist, DG Comp, currently Analysis Group), & Angelos Stenimachitis (Univ. of Essex, Economics, Ph.D. program and Compass Lexecon), Ecosystem Definition and Detection in the Pharmaceutical Industry

Keith Maskus (Univ. of Colorado, formerly World Bank) and Christine McDaniel (World Bank), The Role of Intellectual Property Assets in Financing Innovation in Biopharmaceutical Firms Across Countries

Panel 2: Intellectual Property Rights and Global Biopharmaceutical Markets

Olena Ivus, Associate Professor E. Marie Shantz Fellow of Business Economics, Queen’s University, Canada and Walter Park (American Univ.), Global Value Chains, Patent Protection, and Knowledge Diffusion in Pharmaceuticals

Chirantan Chatterjee (Univ. of Sussex), The Long Way to Innovation – India’s Biopharmaceutical Industry 2 Decades after WTO-TRIPs

Panel 3: Evidence on Patent Term and Biopharmaceutical Innovation

Gabriele Pellegrino (Universita Cattolica del Sacro Cuore), Fabio Montobbio (same) & Satayaki Chakravarty (same), Patent Term Extensions through the EU Supplemental Patent Certificate Regime

Gaetan de Rassenfosse (EPFL, Ecole Polytechnique Federale de Lausanne) & Kyle Higham (Motu Economic & Public Policy Research), Patent Pendency and Innovation Outcomes in Pharmaceutical and Medical Device Sectors

Simona Gamba (University of Milan) and Laura Magazzini (Sant’ Anna School of Advanced Studies), Heterogeneous Innovation Responses to Orphan Drug Regulation

Keynote Lunch Address: Speaker to be announced.

Panel 4: Reinvigorating the European and Global Biopharmaceutical Ecosystem

Fredrik Erixon (European Center for International Political Economy), Andrea Dugo (ECIPE), Oscar Guinea (ECIPE), Beyond the Blockbuster: Intellectual Property and the Emerging Transformation of European Life Sciences

Timo Minssen (Univ. of Copenhagen, Law), Strategic Partnerships, Coopetition and Health Sovereignty: Recalibrating Incentives, Regulation, and Tech Transfer for a More Competitive Europe

Alden Abbott (George Mason Univ., Mercatus Institute) and Satya Marar (George Mason Univ., Mercatus Institute), Fostering Higher Foreign Contributions to Pharma R&D Through Trade Deals, Deregulation and Aligning Incentives

Panel 5: Evidence on Price Controls, Pricing Policy, and Biopharmaceutical Innovation

Harry Bowen (Queens Univ. of Charlotte) & Duane Schulthess (Vital Transformation), Effects of European Price Control on U.S. Pharmaceutical Innovation

Stephen Ezell (Information Technology & Information Foundation) & Sandra Barbosu (ITIF), Price Control Regimes and Pharmaceutical Innovation in Japan, Europe, and the United States

Katharina Blankart (Bern University of Applied Sciences, Switzerland), Paul Gerhard Peters (ZEW Mannheim) & Simon Reif (ZEW Mannheim), Paragraph Drug Availability – Value-based pricing and biopharmaceutical innovation